Microdose semaglutide is a telehealth and compounding industry term for doses below the FDA-approved 0.25 mg weekly starting dose of Ozempic and Wegovy. Typical microdosing protocols range from 0.05 mg to 0.2 mg weekly, delivered from compounded multi-dose vials. These doses have not been studied in large randomized clinical trials, are not included in the approved prescribing information for any semaglutide product, and exist largely as a product of the 2022–2024 semaglutide shortage and the expansion of telehealth compounding.
Where the Term Comes From
Semaglutide shortages in 2022 created a legal opening for US pharmacies to compound the drug. Compounding pharmacies could produce semaglutide in multi-dose vials, and telehealth clinics could direct patients to draw small, flexible volumes with insulin-style syringes. Some clinicians and platforms began prescribing doses below the approved 0.25 mg initiation level — especially for patients who wanted to minimize nausea, manage cost, or continue therapy after reaching a weight goal. The term “microdose” emerged in marketing to describe this practice, borrowing language from psychedelic and hormone microdosing trends.
What the Evidence Does and Does Not Say
Semaglutide was developed and tested at specific doses. The phase 3 SUSTAIN program for Ozempic evaluated 0.5 mg and 1 mg weekly. The STEP program for Wegovy evaluated doses titrating up to 2.4 mg weekly. No pivotal phase 3 program has evaluated weight-loss or glycemic efficacy at doses below 0.25 mg weekly.
What this means in practical terms:
- There are no large randomized trials showing clinically meaningful A1C reduction or weight loss at microdoses
- Pharmacokinetic modeling suggests much lower receptor engagement at sub-0.25 mg weekly exposure
- Reported outcomes at microdoses are drawn from uncontrolled telehealth case series and patient self-report, not controlled trials
- Side-effect reduction at lower doses is plausible but is balanced against reduced therapeutic effect
Rationales Telehealth Clinics Cite
Clinics that offer microdosing typically give one of four reasons:
- Side-effect mitigation. Starting below 0.25 mg is presented as a way to reduce nausea and gastrointestinal effects during initiation.
- Cost management. Lower doses stretch a compounded vial further, reducing monthly cost compared with weekly 0.25 mg initiation.
- Maintenance after goal weight. Patients who have lost target weight are maintained on microdoses in an effort to prevent regain.
- Subclinical use. Some marketing frames microdosing as a “metabolic optimization” tool for people without diabetes or obesity, which is a particularly unsupported use.
Approved Doses vs. Microdoses
| Regimen | Weekly dose | FDA-approved? | Evidence quality | Typical use |
|---|---|---|---|---|
| Microdose semaglutide | 0.05–0.2 mg | No | Uncontrolled case series | Compounded, off-label |
| Ozempic initiation | 0.25 mg | Yes | Randomized trials | First 4 weeks only |
| Ozempic first maintenance | 0.5 mg | Yes | Randomized trials | Type 2 diabetes |
| Ozempic standard maintenance | 1 mg | Yes | Randomized trials | Type 2 diabetes |
| Ozempic high dose | 2 mg | Yes | Randomized trials | Type 2 diabetes |
| Wegovy maintenance | 2.4 mg | Yes | Randomized trials | Weight management |
Quality and Safety Considerations
Microdose semaglutide is almost always delivered from compounded vials. That means the quality-control concerns that apply to compounded semaglutide generally — variable potency, unapproved salt forms, dosing errors from insulin syringes, and limited FDA oversight — apply here as well. The FDA’s consumer communication on compounded semaglutide documents dosing errors, adverse events, and product recalls.
Microdosing also introduces an additional variable: patients measuring very small volumes (sometimes two to four insulin units) where a single unit off is a substantial percentage error. Accuracy depends heavily on patient technique, vial concentration, and syringe calibration.
Side Effects at Lower Doses
Side effects of semaglutide are dose-related but not uniformly so. Even at subtherapeutic doses, some patients experience nausea, constipation, fatigue, and reflux. Uncommon but serious risks — pancreatitis, gallbladder disease, thyroid tumors (boxed warning), and severe hypoglycemia when combined with insulin or sulfonylureas — are not dose-specific in the approved label. Microdosing does not eliminate these risks; it only likely reduces their incidence.
Maintenance After Weight Loss
One of the more discussed uses of microdosing is long-term weight-loss maintenance. Trial data from the STEP program suggest significant weight regain when semaglutide is stopped. Whether stepping down to microdoses preserves weight loss better than tapering off entirely is not well studied. Clinicians vary in approach — some continue full dose indefinitely, some taper to the lowest tolerated approved dose, and some use compounded microdoses off-label.
If You Have Prediabetes
Microdose semaglutide is not supported as a prediabetes treatment. The Standards of Care emphasize lifestyle change and, for selected higher-risk patients, metformin. For an overview of where medications fit, see our treatment hub. For dietary strategies with the strongest evidence, visit the diet and nutrition hub. For information on your lab numbers, see our A1C levels guide, and for a deeper look at whether prediabetes can be reversed through non-pharmacologic means, the reversibility article summarizes the evidence.
Questions to Ask If Microdosing Is Offered
- What evidence specifically supports the dose you are recommending?
- Is the compounded product made by a licensed 503A or 503B pharmacy, and what is the base molecule?
- How will dosing accuracy be verified, and what training is provided for syringe technique?
- What is the plan if I experience serious side effects, and who will see me in person?
- What are the total annual costs and cancellation terms?
The Bottom Line
Microdose semaglutide is an off-label, compounding-driven practice without large trial evidence. It may reduce side effects and extend a vial, but it does not match the evidence base supporting FDA-approved doses. Anyone considering microdosing should work with a qualified clinician, understand the trade-offs, and recognize that the practice exists largely because of the compounding market rather than because science has determined this is the optimal way to use semaglutide.
